Top Stories Monday, November 21, 2016 Chiesi Farmaceutici has bought Atopix Therapeutics for its pipeline of asthma treatments. The buyout gives Chiesi an orally administered CRTh2 antagonist that Atopix is testing in a Phase II trial of severe eosinophilic asthma patients. Monday, November 21, 2016 Ruga has fully uncloaked today and rebrands as Aravive Biologics as it also moves its ops to Houston, Texas, and out of the Bay Area. Monday, November 21, 2016 Celgene, already heavily involved with the biotech, has announced a deeper tie-up with private co Triphase Accelerator that sees it buy into its proteasome inhibitor. Monday, November 21, 2016 Acorda’s poststroke walking difficulties med dalfampridine doesn’t work, and the biotech is pulling the plug as it looks across to its Parkinson’s and migraine assets going forward. Monday, November 21, 2016 Viralytics just reported impressive data for its virus-based cancer therapy that could bring commercial partners out of the woodwork, say analysts. Monday, November 21, 2016 Novartis has scrapped its commitment to start clinical trials of its Google-partnered contact lenses in 2016. Having predicted 14 months ago that testing in humans would start this year, Novartis has now told Reuters “it is too early to say when exactly human clinical trials for these lenses will begin.” Monday, November 21, 2016 Sanofi and Regeneron’s wannabe blockbuster sarilumab may be delayed, but once it hits the market, it will have to take on AbbVie’s behemoth Humira. Good thing it's posted new data that could help arm it for the fight. Monday, November 21, 2016 An FDA “Breakthrough” tag, which has been around since 2012, was once a highly coveted badge that in essence allows the regulator to help speed up development of new meds, and it was believed initially that these would be fairly rare occurrences held back for some truly innovative treatments. Now, however, the FDA seems to be giving out these designations like candy, and not a month appears to go past without yet another experimental med gaining this label. | | | Patrick Soon-Shiong has had dinner with President-elect Donald Trump. LA Times British biotech Astex has teamed up with the Dementia Discovery Fund as a strategic investor. Statement Rosetta Genomics has penned an R&D collab that is designed to help predict responses to Bristol's Opdivo in lung cancer patients. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico Immunotherapy: Mapping the Future of Cancer Drug Discovery November 28, 2016 | Munich, Germany 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd | 